Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Spark Therapeutics (ONCE) PT Lowered to $77 at BarclaysAugust 8, 2018 5:11 AM BMO Capital Downgrades Spark Therapeutics (ONCE) to Market PerformAugust 7, 2018 4:23 PM Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson HumphreyAugust 7, 2018 3:32 PM Spark Therapeutics (ONCE) PT Lowered to $80 at CowenAugust 7, 2018 3:31 PM Spark Therapeutics (ONCE) PT Lowered to $64 at RBC CapitalAugust 7, 2018 2:31 PM BioMarin Pharma (BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (ONCE)August 7, 2018 8:20 AM Form 8-K Spark Therapeutics, Inc. For: Aug 07August 7, 2018 7:59 AM Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07August 7, 2018 7:35 AM Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business ProgressAugust 7, 2018 7:30 AM